Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00582_DB01142_nanopub.RAuPVJdzstoHPRkPyoRlv9agj9rtxRhSzdJ-fodXXaxHM#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00582_DB01142 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00582_DB01142 label "DDI between Voriconazole and Doxepin - Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of doxepin by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of doxepin if voriconazole is initiated, discontinued or dose changed. [drugbank_resource:DB00582_DB01142]" assertion.
- drugbank_resource:DB00582_DB01142 identifier "drugbank_resource:DB00582_DB01142" assertion.
- drugbank_resource:DB00582_DB01142 title "DDI between Voriconazole and Doxepin - Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may also increase the serum concentration of doxepin by decreasing its metabolism. Consider alternate therapy or monitor for QTc prolongation and changes in the therapeutic and adverse effects of doxepin if voriconazole is initiated, discontinued or dose changed." assertion.
- drugbank:DB00582 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00582_DB01142 assertion.
- drugbank:DB01142 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00582_DB01142 assertion.